{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:49:11Z","timestamp":1794635351614,"version":"4.9.1"},"reference-count":299,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Grant Agency of the Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["AZV 17-30920A"],"award-info":[{"award-number":["AZV 17-30920A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Grant Agency of the Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NV19-09-00237"],"award-info":[{"award-number":["NV19-09-00237"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Charles University Research Centre","doi-asserted-by":"publisher","award":["UNCE\/MED\/006"],"award-info":[{"award-number":["UNCE\/MED\/006"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Sustainability Program I","award":["Nr. LO1503"],"award-info":[{"award-number":["Nr. LO1503"]}]},{"name":"Ministry of Education Youth and Sports of the Czech Republic","id":[{"id":"https:\/\/ror.org\/037n8p820","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Grant Agency of the Charles University","award":["GAUK 302119"],"award-info":[{"award-number":["GAUK 302119"]}],"id":[{"id":"https:\/\/ror.org\/024d6js02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pharmthera.2019.107447","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T11:28:39Z","timestamp":1574162919000},"page":"107447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":915,"special_numbering":"C","title":["5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future"],"prefix":"10.1016","volume":"206","author":[{"given":"Sona","family":"Vodenkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Cervena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Veskrnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Vodicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Vymetalkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107447_bb0005","series-title":"In","volume":"Vol. 2019","author":"AdisInsight. Emitefur","year":"2006"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0010","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.3748\/wjg.v20.i20.6092","article-title":"Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?","volume":"20","author":"Aguado","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/COC.0000000000000185","article-title":"The efficacy of adjuvant chemotherapy in patients with stage II\/III resected rectal cancer treated with neoadjuvant chemoradiation therapy","volume":"40","author":"Ahn","year":"2017","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4251\/wjgo.v6.i6.177","article-title":"Current status of pharmacological treatment of colorectal cancer","volume":"6","author":"Akhtar","year":"2014","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clcc.2016.11.001","article-title":"Response to chemotherapy and prognosis in metastatic colorectal cancer with DNA deficient mismatch repair","volume":"16","author":"Alex","year":"2017","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.2003.05.044","article-title":"Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and bowel project collaborative study","volume":"21","author":"Allegra","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-27-54","article-title":"Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy","volume":"27","author":"Amstutz","year":"2008","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0040","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-06-2960","article-title":"5-fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity","volume":"67","author":"An","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CAD.0b013e3283293fd4","article-title":"Pharmacology and therapeutic efficacy of capecitabine: Focus on breast and colorectal cancer","volume":"20","author":"Aprile","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0050","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdf327","article-title":"Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil","volume":"13","author":"Aschele","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0055","first-page":"1855","article-title":"Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules","volume":"52","author":"Aschele","year":"1992","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0060","doi-asserted-by":"crossref","first-page":"649","DOI":"10.21873\/invivo.11523","article-title":"Clinical implications of mismatch repair status in patients with high-risk stage II colon cancer","volume":"33","author":"Baek","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0065","first-page":"789","article-title":"Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil","volume":"13","author":"Bagrij","year":"1993","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JCO.2000.18.4.915","article-title":"Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil","volume":"18","author":"Baker","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0075","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"Bardelli","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0085","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.2004.05.063","article-title":"American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer","volume":"22","author":"Benson","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0090","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/1097-0142(197208)30:2<390::AID-CNCR2820300214>3.0.CO;2-E","article-title":"Results of treatment of malignant tumors with ftorafur","volume":"30","author":"Blokhina","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0095","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2009.25.2106","article-title":"Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05","volume":"28","author":"Boige","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0100","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1111\/j.1742-4658.2009.07383.x","article-title":"MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells","volume":"276","author":"Borralho","year":"2009","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0105","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2019.107447_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000055262","article-title":"Fluoropyrimidines: a critical evaluation","volume":"57","author":"Brito","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0115","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1200\/JCO.2001.19.11.2778","article-title":"Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients","volume":"19","author":"Broet","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/med.20159","article-title":"The dual role of thymidine phosphorylase in cancer development and chemotherapy","volume":"29","author":"Bronckaers","year":"2009","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30503-5","article-title":"TAS-102 in metastatic colorectal cancer","volume":"19","author":"Burki","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0130","first-page":"3717","article-title":"Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose","volume":"60","author":"Cao","year":"2000","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0026-895X(25)14548-3","article-title":"The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells","volume":"18","author":"Caradonna","year":"1980","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.gastro.2003.12.023","article-title":"Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer","volume":"126","author":"Carethers","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.lungcan.2010.08.022","article-title":"Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC","volume":"71","author":"Chang","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0150","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2147\/CMAR.S174584","article-title":"Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: A meta-analysis","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Management and Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0155","doi-asserted-by":"crossref","first-page":"1740936","DOI":"10.1155\/2016\/1740936","article-title":"Cancer stem cell quiescence and plasticity as major challenges in cancer therapy","volume":"2016","author":"Chen","year":"2016","journal-title":"Stem Cells International"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107447_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12156-011-0074-3","article-title":"Capecitabine versus 5-fluorouracil in colorectal cancer: Where are we now?","volume":"5","author":"Chintala","year":"2011","journal-title":"Oncology Reviews"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0165","article-title":"Oral versus intravenous fluoropyrimidines for colorectal cancer","volume":"7","author":"Chionh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0026-895X(25)13411-1","article-title":"Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma","volume":"43","author":"Chu","year":"1993","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0175","first-page":"207","article-title":"Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells","volume":"14","author":"Chu","year":"1994","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3835(00)00535-8","article-title":"Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells","volume":"159","author":"Chung","year":"2000","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0926-6550(63)90323-2","article-title":"Inhibition of biosynthesis of the nucleic acid pyrimidine bases by N-formylbiuret, a degradation product of 5-azauracil","volume":"72","author":"Cihak","year":"1963","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0190","first-page":"1611","article-title":"Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy","volume":"9","author":"Cohen","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0195","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/jm00197a010","article-title":"Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5\u2032-deoxy-5-fluoropyrimidine nucleosides","volume":"22","author":"Cook","year":"1979","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010107","article-title":"Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients","volume":"18","author":"Copija","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0205","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-011-1666-0","article-title":"5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: A report of two cases","volume":"68","author":"Cordier","year":"2011","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0210","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1634\/theoncologist.2017-0573","article-title":"Trifluridine\/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: A multicenter register in the frame of the Italian compassionate use program","volume":"23","author":"Cremolini","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0215","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2011.321","article-title":"P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: Implication in resistance","volume":"31","author":"de la Cruz-Morcillo","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/COC.0b013e31826e0703","article-title":"A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer","volume":"37","author":"Cubillo","year":"2014","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0163-7258(90)90080-L","article-title":"Metabolism of pyrimidine analogues and their nucleosides","volume":"48","author":"Daher","year":"1990","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0230","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1749-6632.1991.tb27255.x","article-title":"Biochemical basis for circadian-dependent metabolism of fluoropyrimidines","volume":"618","author":"Daher","year":"1991","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0235","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.febslet.2005.12.036","article-title":"Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)","volume":"580","author":"Deeley","year":"2006","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0240","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317697553","article-title":"Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance","volume":"39","author":"Deng","year":"2017","journal-title":"Tumour Biology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0245","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.18632\/oncotarget.2770","article-title":"A pathophysiological view of the long non-coding RNA world","volume":"5","author":"Di Gesualdo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0250","first-page":"23","article-title":"The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology","volume":"12","author":"Diasio","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0255","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2052-8426-2-16","article-title":"MicroRNAs: Short non-coding players in cancer chemoresistance","volume":"2","author":"Donzelli","year":"2014","journal-title":"Molecular and Cellular Therapies"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/tera.1420190203","article-title":"Embryotoxicity of transplacentally and intraamniotically administered 6-azauridine in mice","volume":"19","author":"Dostal","year":"1979","journal-title":"Teratology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0270","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0275","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1124\/dmd.115.064824","article-title":"Potent and selective inhibition of plasma membrane monoamine transporter by HIV protease inhibitors","volume":"43","author":"Duan","year":"2015","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0280","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12307-015-0173-y","article-title":"Thymidine Phosphorylase in cancer; enemy or friend?","volume":"9","author":"Elamin","year":"2016","journal-title":"Cancer Microenvironment"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0285","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1200\/JCO.2002.09.091","article-title":"Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses","volume":"20","author":"Etienne","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0290","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00008571-200412000-00001","article-title":"Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients","volume":"14","author":"Etienne","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0295","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-42059-2_11","article-title":"Involvement of non-coding RNAs in chemo- and Radioresistance of colorectal cancer","volume":"937","author":"Fanale","year":"2016","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0300","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.cad.0000198914.83195.61","article-title":"Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: An in-vitro study","volume":"17","author":"Fanciullino","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0305","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2217\/epi-2017-0041","article-title":"Overcoming chemoresistance in cancer stem cells with the help of microRNAs in colorectal cancer","volume":"9","author":"Fesler","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0310","first-page":"1","article-title":"The role of DNA mismatch repair in drug resistance","volume":"4","author":"Fink","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0315","first-page":"991","article-title":"Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation","volume":"1","author":"Fischel","year":"1995","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0320","first-page":"2223","article-title":"Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion","volume":"40","author":"Fraile","year":"1980","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0325","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0330","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3892\/or.2016.5259","article-title":"miR-20b reduces 5-FU resistance by suppressing the ADAM9\/EGFR signaling pathway in colon cancer","volume":"37","author":"Fu","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0335","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21873\/anticanres.11313","article-title":"Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor","volume":"37","author":"Fujiyoshi","year":"2017","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0340","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0959-8049(01)00174-5","article-title":"Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo","volume":"37","author":"Fukushima","year":"2001","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-10-1","article-title":"The immune score as a new possible approach for the classification of cancer","volume":"10","author":"Galon","year":"2012","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0350","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.2147\/OTT.S140854","article-title":"Cancer cell dormancy: Mechanisms and implications of cancer recurrence and metastasis","volume":"10","author":"Gao","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0355","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjc.6605261","article-title":"Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: A phase II study of the Spanish GOTI group","volume":"101","author":"Garcia-Alfonso","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0360","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.bjc.6605907","article-title":"Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer","volume":"103","author":"Garcia-Alfonso","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0365","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0370","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc2892","article-title":"Evolutionary dynamics of cancer prevention","volume":"10","author":"Gatenby","year":"2010","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0375","first-page":"581","article-title":"Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells","volume":"6","author":"Geoffroy","year":"1994","journal-title":"Oncology Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0380","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0385","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0390","first-page":"332","article-title":"Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities","volume":"176","author":"Giller","year":"1967","journal-title":"Doklady Akademii Nauk SSSR"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0395","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bjc.6603639","article-title":"Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels","volume":"96","author":"Giovannetti","year":"2007","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0400","first-page":"54","article-title":"The thrombogenicity of 6-azouridine","volume":"8","author":"Gitel","year":"1979","journal-title":"Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0405","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0410","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.23740","article-title":"Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer","volume":"123","author":"Gosens","year":"2008","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0415","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0420","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0163-7258(89)90084-3","article-title":"Enhancement of 5-fluorouracil's anticancer activity by dipyridamole","volume":"40","author":"Grem","year":"1989","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0425","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1515\/BC.2003.089","article-title":"Contribution of the absolutely conserved B8Gly to the foldability of insulin","volume":"384","author":"Guo","year":"2003","journal-title":"Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0430","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2011.07.026","article-title":"Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells","volume":"146","author":"Gupta","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0435","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605052","article-title":"Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer","volume":"100","author":"Gusella","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0445","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/ijc.23852","article-title":"Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes","volume":"124","author":"Gustavsson","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0450","doi-asserted-by":"crossref","first-page":"23713","DOI":"10.18632\/oncotarget.15785","article-title":"dUTPase inhibition augments replication defects of 5-fluorouracil","volume":"8","author":"Hagenkort","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0455","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clcc.2016.07.005","article-title":"Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102","volume":"16","author":"Hamauchi","year":"2017","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0460","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834015614530","article-title":"Pharmacologic resistance in colorectal cancer: A review","volume":"8","author":"Hammond","year":"2016","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0465","first-page":"965","article-title":"Microbial studies of 6-azauracil, an antagonist of uracil","volume":"16","author":"Handschumacher","year":"1956","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0470","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0475","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0480","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jcp.10256","article-title":"Overcoming resistance of cancer cells to apoptosis","volume":"196","author":"Hersey","year":"2003","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0485","first-page":"2401","article-title":"Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas","volume":"6","author":"Hinoshita","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0490","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/mutage\/ger075","article-title":"The role of ABC transporters in progression and clinical outcome of colorectal cancer","volume":"27","author":"Hlavata","year":"2012","journal-title":"Mutagenesis"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0495","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/1841213a0","article-title":"Massive incorporation of 5-fluorouracil into a bacterial ribonucleic acid","volume":"184","author":"Horowitz","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0500","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/yea.1516","article-title":"Evidence for distinct DNA- and RNA-based mechanisms of 5-fluorouracil cytotoxicity in Saccharomyces cerevisiae","volume":"24","author":"Hoskins","year":"2007","journal-title":"Yeast"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0505","unstructured":"https:\/\/clinicaltrials.gov\/. (2019). U.S. National Library of Medicine. In."},{"key":"10.1016\/j.pharmthera.2019.107447_bb0510","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.3748\/wjg.v22.i30.6876","article-title":"Mechanisms of drug resistance in colon cancer and its therapeutic strategies","volume":"22","author":"Hu","year":"2016","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0515","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.phymed.2015.03.010","article-title":"Sensitivity of apoptosis-resistant colon cancer cells to tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity","volume":"22","author":"Hu","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0520","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1535-7163.MCT-08-0716","article-title":"Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance","volume":"8","author":"Humeniuk","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0525","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0091270010396710","article-title":"Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer","volume":"52","author":"Ibrahim","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0530","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/onc.2013.398","article-title":"Impaired DICER1 function promotes stemness and metastasis in colon cancer","volume":"33","author":"Iliou","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0535","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1773-2247(09)50005-6","article-title":"Permeability of 5-fluorouracil and its prodrugs in Caco-2 cell monolayers: Evidence for shift from paracellular to transcellular transport by prodrug formation","volume":"19","author":"Imoto","year":"2009","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0540","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0026-895X(25)14573-2","article-title":"Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine","volume":"21","author":"Ingraham","year":"1982","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0545","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"International Transporter, C","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0550","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bbrc.2018.04.120","article-title":"Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types","volume":"500","author":"Ishiba","year":"2018","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0555","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2407-8-188","article-title":"Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy","volume":"8","author":"Ishikawa","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0560","first-page":"112","article-title":"Role of uridine phosphorylase for antitumor activity of 5\u2032-deoxy-5-fluorouridine","volume":"71","author":"Ishitsuka","year":"1980","journal-title":"Gan"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0565","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4161\/cbt.12.8.17169","article-title":"DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells","volume":"12","author":"Iwaizumi","year":"2011","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0570","first-page":"295","article-title":"Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: Confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees","volume":"30","author":"Iyevleva","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0575","article-title":"Folate antagonists as therapeutic agents","volume":"74","author":"Jackson","year":"1984","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0580","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1200\/JCO.2005.06.219","article-title":"Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity","volume":"23","author":"Jakobsen","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0585","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/jrms.JRMS_106_18","article-title":"Effectiveness of adjuvant chemotherapy in patients with stage II colorectal cancer: A multicenter retrospective study","volume":"24","author":"Jalaeikhoo","year":"2019","journal-title":"Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0590","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/dna.2015.3120","article-title":"miR-450b-5p suppresses stemness and the development of Chemoresistance by targeting SOX2 in colorectal cancer","volume":"35","author":"Jin","year":"2016","journal-title":"DNA and Cell Biology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0595","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/CBM-2006-21-206","article-title":"Chemotherapeutic implications in microsatellite unstable colorectal cancer","volume":"2","author":"Jo","year":"2006","journal-title":"Cancer Biomarkers"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0600","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/00001813-200109000-00001","article-title":"Capecitabine: A novel agent for the treatment of solid tumors","volume":"12","author":"Johnston","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0605","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0610","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","article-title":"Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study","volume":"16","author":"Kasi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0615","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-002-0526-3","article-title":"Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens","volume":"51","author":"Katsumata","year":"2003","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0620","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11864-015-0348-2","article-title":"Microsatellite instability testing and its role in the management of colorectal cancer","volume":"16","author":"Kawakami","year":"2015","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0625","first-page":"4929","article-title":"Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey","volume":"44","author":"Kerr","year":"1984","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0630","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3393\/ac.2014.30.1.5","article-title":"Is a microsatellite instability still useful for tailored treatment in stage II and III colon cancer?","volume":"30","author":"Kim","year":"2014","journal-title":"Ann Coloproctol"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0635","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.20140","article-title":"MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells","volume":"110","author":"Klappe","year":"2004","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0640","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/bj1060167","article-title":"Effects of 5-fluorouracil and 6-azauracil on the synthesis of ribonucleic acid and protein in Saccharomyces carlsbergensis","volume":"106","author":"de Kloet","year":"1968","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0645","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0163-7258(89)90111-3","article-title":"Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue","volume":"41","author":"Klubes","year":"1989","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0650","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015","volume":"19","author":"Kohne","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0655","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ijc.24726","article-title":"Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer","volume":"126","author":"Koizumi","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0660","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0665","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0670","first-page":"1631","article-title":"NFkappaB-associated pathways in progression of Chemoresistance to 5-fluorouracil in an in vitro model of colonic carcinoma","volume":"36","author":"Korber","year":"2016","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0675","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.1227670","article-title":"Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer","volume":"339","author":"Kreso","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0680","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/147323001003800313","article-title":"Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"The Journal of International Medical Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0685","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0690","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12885-016-2826-8","article-title":"Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma","volume":"16","author":"Kunicka","year":"2016","journal-title":"BMC Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.pharmthera.2019.107447_bb0695","doi-asserted-by":"crossref","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","article-title":"Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Labianca","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0700","first-page":"3493","article-title":"dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: Association with survival and response to 5-fluorouracil in colorectal cancer","volume":"60","author":"Ladner","year":"2000","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0705","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ctrv.2005.09.009","article-title":"Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer","volume":"31","author":"Lamberti","year":"2005","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0710","first-page":"2289","article-title":"The oral fluoropyrimidines in cancer chemotherapy","volume":"5","author":"Lamont","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0715","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1188\/14.CJON.581-585","article-title":"5-fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: Implications for practice","volume":"18","author":"Latchman","year":"2014","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0720","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/1078-0432.CCR-04-0169","article-title":"Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy","volume":"10","author":"Lecomte","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0725","doi-asserted-by":"crossref","first-page":"540","DOI":"10.14348\/molcells.2014.0151","article-title":"A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells","volume":"37","author":"Lee","year":"2014","journal-title":"Molecules and Cells"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0730","doi-asserted-by":"crossref","first-page":"54199","DOI":"10.18632\/oncotarget.14909","article-title":"Base excision repair imbalance in colorectal cancer has prognostic value and modulates response to chemotherapy","volume":"8","author":"Leguisamo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0735","first-page":"1243","article-title":"p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival","volume":"4","author":"Lenz","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0740","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.ejca.2010.02.021","article-title":"Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model","volume":"46","author":"Li","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0745","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1245\/s10434-008-0260-0","article-title":"Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells","volume":"16","author":"Li","year":"2009","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0750","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.ejca.2012.12.013","article-title":"The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil","volume":"49","author":"Li","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0755","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1476-5381.2009.00423.x","article-title":"DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets","volume":"158","author":"Li","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0760","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2407-4-11","article-title":"Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy","volume":"4","author":"Libra","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0765","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1472-6890-14-25","article-title":"Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer","volume":"14","author":"Lindskog","year":"2014","journal-title":"BMC Clinical Pathology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0770","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5732\/cjc.009.10666","article-title":"Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines","volume":"29","author":"Liu","year":"2010","journal-title":"Chinese Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0775","first-page":"2644","article-title":"The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates","volume":"62","author":"Longley","year":"2002","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0780","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0785","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0790","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0795","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1007\/s13277-015-4755-6","article-title":"Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells","volume":"37","author":"Lv","year":"2016","journal-title":"Tumour Biology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2019.107447_bb0800","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10120-003-0232-9","article-title":"S-1 in gastric cancer: A comprehensive review","volume":"6","author":"Maehara","year":"2003","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0805","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review","volume":"7","author":"Malet-Martino","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0810","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: A brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Advanced Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0815","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ijc.20487","article-title":"Single nucleotide polymorphism in the 5\u2032 tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients","volume":"112","author":"Marcuello","year":"2004","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0820","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00280-005-0089-1","article-title":"Methylenetetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?","volume":"57","author":"Marcuello","year":"2006","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0825","doi-asserted-by":"crossref","first-page":"13438","DOI":"10.18632\/oncotarget.24412","article-title":"Trifluridine\/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression","volume":"9","author":"Matsuoka","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0830","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","article-title":"Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics","volume":"3","author":"Mattison","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0835","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0026-895X(25)13666-3","article-title":"Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells","volume":"43","author":"Mauro","year":"1993","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0840","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0845","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1200\/JCO.2005.05.2084","article-title":"Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Meropol","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0850","first-page":"2371","article-title":"High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil","volume":"4","author":"Metzger","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0855","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0959-8049(99)00211-7","article-title":"Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?","volume":"36","author":"Milano","year":"2000","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0860","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00686631","article-title":"Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells","volume":"35","author":"Mitrovski","year":"1994","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0865","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-fu metabolism in cancer and orally-administrable 5-fu drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0870","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1517\/14656566.2014.937706","article-title":"Efficacy of S-1 in colorectal cancer","volume":"15","author":"Miyamoto","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0875","doi-asserted-by":"crossref","first-page":"5769591","DOI":"10.1155\/2018\/5769591","article-title":"The molecular basis and therapeutic potential of Let-7 MicroRNAs against colorectal cancer","volume":"2018","author":"Mizuno","year":"2018","journal-title":"Canadian Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0880","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078172","article-title":"New insights into the RNA-based mechanism of action of the anticancer drug 5\u2032-fluorouracil in eukaryotic cells","volume":"8","author":"Mojardin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0885","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/pgs.10.188","article-title":"Systems pharmacology assessment of the 5-fluorouracil pathway","volume":"12","author":"Muhale","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0890","first-page":"751","article-title":"The impact of thymidylate synthase and methylenetetrahydrofolate reductase genotypes on sensitivity to 5-fluorouracil treatment in colorectal cancer cells","volume":"55","author":"Naghibalhossaini","year":"2017","journal-title":"Acta Medica Iranica"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0895","first-page":"317","article-title":"Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with Chemoresponse to S-1 in colon cancer","volume":"3","author":"Nakajima","year":"2006","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0900","series-title":"PubChem Database. Eniluracil, CID=43157","volume":"Vol. 2019","author":"National Center for Biotechnology Information","year":"2005"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0905","series-title":"Colon Cancer","volume":"Vol. 2019","author":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2019"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0910","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0915","first-page":"2620","article-title":"Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves","volume":"5","author":"Nishiyama","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0920","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdh264","article-title":"5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers","volume":"15","author":"Noordhuis","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0925","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.2010.28.9538","article-title":"Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II\/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin","volume":"28","author":"O'Connell","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0930","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1535-7163.MCT-06-0529","article-title":"MRP8\/ABCC11 directly confers resistance to 5-fluorouracil","volume":"6","author":"Oguri","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0935","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/biores.2014.0035","article-title":"Autophagy in cancer stem cells: A potential Link between Chemoresistance, recurrence, and metastasis","volume":"4","author":"Ojha","year":"2015","journal-title":"Biores Open Access"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0940","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0945","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00432-010-0826-7","article-title":"Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil","volume":"136","author":"Paez","year":"2010","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0950","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.3748\/wjg.v20.i29.9775","article-title":"Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years","volume":"20","author":"Panczyk","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0955","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/vhrm.2006.2.2.97","article-title":"Clinical implications of angiogenesis in cancers","volume":"2","author":"Pang","year":"2006","journal-title":"Vascular Health and Risk Management"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0960","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0163-7258(90)90056-8","article-title":"Metabolism and mechanism of action of 5-fluorouracil","volume":"48","author":"Parker","year":"1990","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0965","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2217\/fon-2018-0147","article-title":"Trifluridine\/tipiracil: An emerging strategy for the management of gastrointestinal cancers","volume":"14","author":"Peeters","year":"2018","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0970","doi-asserted-by":"crossref","first-page":"34322","DOI":"10.18632\/oncotarget.9107","article-title":"MEK5\/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism","volume":"7","author":"Pereira","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0975","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CAD.0b013e328334d88a","article-title":"Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin","volume":"21","author":"Petrioli","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0980","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","article-title":"Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis","volume":"22","author":"Popat","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0985","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1073\/pnas.94.5.1795","article-title":"Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation","volume":"94","author":"Pritchard","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0990","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb0995","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/ijc.23822","article-title":"Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies","volume":"123","author":"Qiu","year":"2008","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1000","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study","volume":"370","author":"Quasar Collaborative","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00109-014-1129-2","article-title":"MicroRNAs: Master regulators of drug resistance, stemness, and metastasis","volume":"92","author":"Raza","year":"2014","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1015","doi-asserted-by":"crossref","first-page":"c1066","DOI":"10.1136\/bmj.c1066","article-title":"Rethinking pragmatic randomised controlled trials: Introducing the \"cohort multiple randomised controlled trial\" design","volume":"340","author":"Relton","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1025","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2015.3119","article-title":"Deficient mismatch repair: Read all about it (review)","volume":"47","author":"Richman","year":"2015","journal-title":"International Journal of Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2019.107447_bb1030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000227738","article-title":"Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation","volume":"54","author":"Rustum","year":"1997","journal-title":"Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0021-9258(18)65456-0","article-title":"The catabolism of uracil in vivo and in vitro","volume":"210","author":"Rutman","year":"1954","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1040","first-page":"832","article-title":"Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies: Experience of 4-years","volume":"23","author":"Saif","year":"2007","journal-title":"Pakistan journal of medical sciences"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/13543780902729412","article-title":"S-1: A promising new oral fluoropyrimidine derivative","volume":"18","author":"Saif","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/13543780902762835","article-title":"Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers","volume":"18","author":"Saif","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1055","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1060","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials","volume":"27","author":"Sargent","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1065","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007287","article-title":"Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer","volume":"4","author":"Sartore-Bianchi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/CAD.0b013e328353f8c7","article-title":"Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study","volume":"23","author":"Sasaki","year":"2012","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1080","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2407-10-370","article-title":"Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells","volume":"10","author":"Sasaki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1085","first-page":"1925","article-title":"New anti-cancer drugs for gastrointestinal cancers","volume":"24","author":"Sasaki","year":"1997","journal-title":"Gan to Kagaku Ryoho"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/pgs.10.167","article-title":"5-fluorouracil pharmacogenomics: Still rocking after all these years?","volume":"12","author":"Scartozzi","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1095","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1517\/13543784.9.7.1635","article-title":"Eniluracil: An irreversible inhibitor of dihydropyrimidine dehydrogenase","volume":"9","author":"Schilsky","year":"2000","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00001813-200402000-00001","article-title":"The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors","volume":"15","author":"Schoffski","year":"2004","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Schuller","year":"2000","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13167-010-0022-5","article-title":"Predictive diagnostics in colorectal cancer: Impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy","volume":"1","author":"Schwarzenbach","year":"2010","journal-title":"The EPMA Journal"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11010-010-0437-2","article-title":"Oxidant\/anti-oxidant dynamics in patients with advanced cervical cancer: Correlation with treatment response","volume":"341","author":"Sharma","year":"2010","journal-title":"Molecular and Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/1078-0432.CCR-07-0425","article-title":"Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients","volume":"14","author":"Sharma","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s13277-015-3106-y","article-title":"Post-transcriptional regulation of long noncoding RNAs in cancer","volume":"36","author":"Shi","year":"2015","journal-title":"Tumour Biology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1130","first-page":"1871","article-title":"Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice","volume":"17","author":"Shirasaka","year":"1990","journal-title":"Gan to Kagaku Ryoho"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/mc.22141","article-title":"Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients","volume":"54","author":"Slyskova","year":"2015","journal-title":"Molecular Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1140","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-12-1380","article-title":"Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas","volume":"18","author":"Slyskova","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jnci\/djh015","article-title":"Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate","volume":"96","author":"Sohn","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1150","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1158\/1078-0432.CCR-08-1422","article-title":"miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit","volume":"14","author":"Song","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1476-4598-9-96","article-title":"Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells","volume":"9","author":"Song","year":"2010","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1160","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/annonc\/mdm599","article-title":"Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy","volume":"19","author":"Soong","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1165","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bjc.2011.594","article-title":"Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable\/metastatic colorectal cancer (mCRC)","volume":"106","author":"Souglakos","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1170","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1073\/pnas.77.8.4966","article-title":"Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation","volume":"77","author":"Spiegelman","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1175","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1074\/jbc.M110.163444","article-title":"Heterogeneous nuclear ribonucleoprotein H1\/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance","volume":"286","author":"Stark","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.12703\/P6-108","article-title":"Management of colorectal cancer","volume":"6","author":"Stintzing","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1185","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnci\/94.12.936","article-title":"Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer","volume":"94","author":"Stoehlmacher","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2159-8290.CD-17-1009","article-title":"Genomic landscape of cell-free DNA in patients with colorectal cancer","volume":"8","author":"Strickler","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2017.08.033","article-title":"Potential role of polymorphisms in the transporter genes ENT1 and MATE1\/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer","volume":"86","author":"Suenaga","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1200","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1038\/srep04694","article-title":"JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy","volume":"4","author":"Sui","year":"2014","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1205","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.7150\/jca.19142","article-title":"HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins","volume":"8","author":"Sun","year":"2017","journal-title":"Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1210","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s12094-015-1318-7","article-title":"MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer","volume":"17","author":"Sun","year":"2015","journal-title":"Clinical & Translational Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1220","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.cgt.7700393","article-title":"Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells","volume":"8","author":"Takebe","year":"2001","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1225","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0959-8049(02)00048-5","article-title":"Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells","volume":"38","author":"Takechi","year":"2002","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1230","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1200\/JCO.1998.16.8.2877","article-title":"Uracil-tegafur in gastric carcinoma: A comprehensive review","volume":"16","author":"Takiuchi","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1389201003378979","article-title":"The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents","volume":"1","author":"Tanaka","year":"2000","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0366-6999.176069","article-title":"Autophagy in 5-fluorouracil therapy in gastrointestinal cancer: Trends and challenges","volume":"129","author":"Tang","year":"2016","journal-title":"Chinese Medical Journal"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1245","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2004.03.104","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis","volume":"22","author":"Thirion","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FPC.0b013e32833c6107","article-title":"PharmGKB summary: Fluoropyrimidine pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1255","first-page":"8695","article-title":"Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing several pro-apoptotic proteins","volume":"15","author":"Tie","year":"2018","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1260","first-page":"553","article-title":"Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil","volume":"68","author":"Toide","year":"1977","journal-title":"Gan"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1265","doi-asserted-by":"crossref","first-page":"33572","DOI":"10.1074\/jbc.M706230200","article-title":"Kinetic mechanism of human dUTPase, an essential nucleotide pyrophosphatase enzyme","volume":"282","author":"Toth","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1275","series-title":"Xeloda FULL PRESCRIBING INFORMATION","volume":"Vol. 2019","author":"U.S. FOOD & DRUG Administration","year":"2015"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1280","first-page":"527","article-title":"Molecular factors of 5-fluorouracil metabolism in colorectal cancer: Analysis of primary tumor and lymph node metastasis","volume":"28","author":"Vallbohmer","year":"2006","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1285","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11605-007-0208-x","article-title":"Towards the molecular characterization of disease: Comparison of molecular and histological analysis of esophageal epithelia","volume":"11","author":"Vallbohmer","year":"2007","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1290","first-page":"413","article-title":"DPD is a molecular determinant of capecitabine efficacy in colorectal cancer","volume":"31","author":"Vallbohmer","year":"2007","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2019.03.001","article-title":"Update on genetic predisposition to colorectal cancer and polyposis","author":"Valle","year":"2019","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1300","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1305","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000263","article-title":"TAS-102 and the quest for predictive biomarkers","volume":"2","author":"van der Velden","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1310","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-15-2783","article-title":"TAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapies","volume":"22","author":"van der Velden","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1315","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/ar800114w","article-title":"Keeping uracil out of DNA: Physiological role, structure and catalytic mechanism of dUTPases","volume":"42","author":"Vertessy","year":"2009","journal-title":"Accounts of Chemical Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1320","doi-asserted-by":"crossref","first-page":"4719194","DOI":"10.1155\/2017\/4719194","article-title":"Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy","volume":"2017","author":"Viale","year":"2017","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1325","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.dnarep.2018.09.006","article-title":"Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients","volume":"72","author":"Vodenkova","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1330","doi-asserted-by":"crossref","DOI":"10.2217\/pgs-2019-0070","article-title":"DNA repair capacity and response to treatment of colon cancer","author":"Vodicka","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1335","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41389-017-0006-6","article-title":"MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9","volume":"6","author":"Vychytilova-Faltejskova","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113356","article-title":"Circulating cell-free DNA and colorectal cancer: A systematic review","volume":"19","author":"Vymetalkova","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.dnarep.2014.03.030","article-title":"Base excision repair: A critical player in many games","volume":"19","author":"Wallace","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1350","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/pgs.10.202","article-title":"Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes","volume":"12","author":"Wang","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1355","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/07357907.2010.535060","article-title":"Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites","volume":"29","author":"Wang","year":"2011","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1360","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.0308716101","article-title":"Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients","volume":"101","author":"Wang","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1365","doi-asserted-by":"crossref","first-page":"11111","DOI":"10.1158\/0008-5472.CAN-07-2858","article-title":"MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy","volume":"67","author":"Weidhaas","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1370","series-title":"Goodman & Gilman's: The Pharmacological Basis of Therapeutics","first-page":"13e","article-title":"Chapter 66: Cytotoxic drugs","author":"Wellstein","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1375","first-page":"163","article-title":"Microsatellite instability status in inflammatory bowel disease and colorectal cancer","volume":"39","author":"Wierzbicki","year":"2009","journal-title":"Ann Acad Med Gedan"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1380","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-11-0221","article-title":"ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients","volume":"71","author":"Wilson","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1385","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","article-title":"Standing the test of time: Targeting thymidylate biosynthesis in cancer therapy","volume":"11","author":"Wilson","year":"2014","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"Suppl. 10","key":"10.1016\/j.pharmthera.2019.107447_bb1390","doi-asserted-by":"crossref","first-page":"x315","DOI":"10.1093\/annonc\/mdl280","article-title":"Chemoresistance in solid tumours","volume":"17","author":"Wilson","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1395","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jcp.1041040305","article-title":"Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells","volume":"104","author":"Wohlhueter","year":"1980","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1400","first-page":"528","article-title":"Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy","volume":"8","author":"Wu","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1405","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/1078-0432.CCR-05-1853","article-title":"Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer","volume":"12","author":"Xi","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1410","doi-asserted-by":"crossref","first-page":"83171","DOI":"10.18632\/oncotarget.20487","article-title":"Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression","volume":"8","author":"Xiao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1415","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.7314\/APJCP.2015.16.8.3395","article-title":"Microarray analysis of long non-coding RNA expression profile associated with 5-fluorouracil-based Chemoradiation resistance in colorectal cancer cells","volume":"16","author":"Xiong","year":"2015","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1420","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of Trifluridine\/Tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1425","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/00365520600994418","article-title":"Modified Irinotecan\/5FU\/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes","volume":"42","author":"Yanagisawa","year":"2007","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1430","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature12451","article-title":"lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs","volume":"500","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1435","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00432-016-2302-5","article-title":"53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway","volume":"143","author":"Yao","year":"2017","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1440","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-15-1370","article-title":"Mechanisms of cancer cell dormancy--another Hallmark of cancer?","volume":"75","author":"Yeh","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1445","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1016\/S0021-9258(18)47554-0","article-title":"Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death","volume":"262","author":"Yoshioka","year":"1987","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1450","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/1078-0432.CCR-06-0549","article-title":"Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency","volume":"12","author":"Yu","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1455","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-015-0372-7","article-title":"miR-21 and miR-145 cooperation in regulation of colon cancer stem cells","volume":"14","author":"Yu","year":"2015","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1460","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1593\/tlo.12397","article-title":"Down-regulation of miR-21 induces differentiation of Chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens","volume":"6","author":"Yu","year":"2013","journal-title":"Translational Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1465","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1248\/bpb.19.94","article-title":"Intestinal brush border transport mechanism of 5-fluorouracil in rats","volume":"19","author":"Yuasa","year":"1996","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1470","first-page":"336","article-title":"Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP","volume":"112","author":"Zhan","year":"1999","journal-title":"Chinese Medical Journal"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jgh.13845","article-title":"Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis","volume":"33","author":"Zhang","year":"2018","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1480","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2007.11.4710","article-title":"Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer","volume":"25","author":"Zhang","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1485","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of resistance to anti-EGFR therapy in colorectal cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1490","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107447_bb1495","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/ijc.27465","article-title":"The association between two polymorphisms in the TS gene and risk of cancer: A systematic review and pooled analysis","volume":"131","author":"Zhou","year":"2012","journal-title":"International Journal of Cancer"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:06:15Z","timestamp":1759010775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":299,"alternative-id":["S0163725819301998"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107447","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107447"}}